Modeling the mechanism pathways of first line drug in Tuberculosis using Petri nets

  • 26 Accesses


Multi-Drug Resistant (MDR) and Extensively Drug-Resistant (XDR) in Tuberculosis (TB) is still a big threat worldwide, as it remains one of the leading causes of death. The main reason behind this is the Mycobacterium tuberculosis bacteria (Mtb) is being resistant towards first line drug (FLD). This is because of the mutation in certain genes like katG, pncA, rpoB, embABC. To have a better understanding of the mechanism behind the susceptibility and resistivity of drugs involved in FLD, we propose a graphical approach of modeling the whole process by using Petri net. The analysis of the model helps in improving the new drug techniques on the way to decrease the rate of MDR-TB and XDR-TB.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9


  1. Achieng RL (2016) Factors associated with tuberculosis treatment outcomes in TB-HIV co-infected and TB only patients in Nyando sub-county (Doctoral dissertation (JOOUST)). Jaramogi Oginga Odinga

  2. Babu GR, Laxminarayan R (2012) The unsurprising story of MDR-TB resistance in India. Tuberculosis 92(4):301–306

  3. Behinaein B, Rudie K, Sangrar W (2018) Petri net siphon analysis and graph theoretic measures for identifying combination therapies in cancer. IEEE/ACM Trans Comput Biol Bioinform (TCBB) 15(1):231–243

  4. Brauer W, Reisig W (2009) Carl Adam Petri and Petri nets. Fundam Concepts Comput Sci 3(5):129–139

  5. Castillo-Chavez C, Song B (2004) Dynamical models of tuberculosis and their applications. Math Biosci Eng 1(2):361–404

  6. Centers for Disease Control and Prevention (CDC) (2006) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000–2004. MMWR 55(11):301

  7. Cherdal S, Mouline S (2018) Modelling and simulation of biochemical processes using Petri nets. Processes 6(8):97

  8. Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas A, Kumar AMV, Satyanarayana S, Lo TQ (2015) Patient and provider reported reasons for lost to follow up in MDRTB treatment: a qualitative study from a drug resistant TB centre in India. PLoS ONE 10(8):e0135802

  9. Dewan R, Anuradha S, Khanna A, Garg S, Singla S, Ish P, Agarwal S (2015) Role of cartridge-based nucleic acid amplification test (CBNAAT) for early diagnosis of pulmonary tuberculosis in HIV. J Indian Acad Clin Med 16:114–7

  10. Dingle NJ, Knottenbelt WJ, Suto T (2009) PIPE2: a tool for the performance evaluation of generalised stochastic Petri Nets. ACM SIGMETRICS Perform Eval Rev 36(4):34–39

  11. Eckleder A, Freytag T (2008) WoPeD 2.0 goes BPEL 2.0. AWPN 380:75–80

  12. Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, Meacci M, Mussini C (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. The Lancet 367(9519):1328–1334

  13. Finkel A (1991) The minimal coverability graph for Petri nets. In: International conference on application and theory of Petri nets. Springer, Berlin, pp 210–243

  14. Gammack D, Ganguli S, Marino S, Segovia-Juarez J, Kirschner DE (2005) Understanding the immune response in tuberculosis using different mathematical models and biological scales. Multiscale Model Simul 3(2):312–345

  15. Gilbert D, Heiner M, Ghanbar L, Chodak J (2019) Spatial quorum sensing modelling using coloured hybrid Petri nets and simulative model checking. BMC Bioinform 20(4):173

  16. Gilpin C, Korobitsyn A, Migliori GB, Raviglione MC, Weyer K (2018) The World Health Organization standards for tuberculosis care and management. Eur Respir J.

  17. Goldman RC, Plumley KV, Laughon BE (2007) The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infect Disord Drug Targets 7(2):73–91

  18. Gupta S, Singh GP, Kumawat S (2019) Petri net recommender system to model metabolic pathway of polyhydroxyalkanoates. Int J Knowl Syst Sci (IJKSS) 10(2):42–59

  19. He GX, van den Hof S, Borgdorff MW, van der Werf MJ, Cheng SM, Hu YL, Wang LX (2010a) Availability of second-line drugs and anti-tuberculosis drug susceptibility testing in China: a situational analysis. Int J Tuberc Lung Dis 14(7):884–889

  20. He GX, Xie YG, Wang LX, Borgdorff MW, Van Der Werf MJ, Fan JH et al (2010b) Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. PLoS ONE 5(5):e10799

  21. Herajy M, Liu F, Heiner M (2018a) Efficient modelling of yeast cell cycles based on multisite phosphorylation using coloured hybrid Petri nets with marking-dependent arc weights. Nonlinear Anal Hybrid Syst 27:191–212

  22. Herajy M, Liu F, Rohr C, Heiner M (2018b) Coloured Hybrid Petri Nets: an adaptable modelling approach for multi-scale biological networks. Comput Biol Chem 76:87–100

  23. Jensen K (1983) High-level Petri nets. In: Applications and theory of Petri nets. Springer, Berlin, pp 166–180

  24. Jensen K, Rozenberg G (2012) High-level Petri nets: theory and application. Springer, New York

  25. Jung J, Kwon M, Bae S, Yim S, Lee D (2018) Petri net-based prediction of therapeutic targets that recover abnormally phosphorylated proteins in muscle atrophy. BMC Syst Biol 12(1):26

  26. Kansal S, Singh GP, Acharya M (2010) On Petri nets generating all the binary n-vectors. Scientiae Mathematicae Japonicae 71(2):209–221

  27. Kansal S, Acharya M, Singh GP (2012) Boolean Petri nets. Petri nets-manufacturing and Computer Science. IntechOpen, London, pp 381–406

  28. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R (2011) Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 2011:405310–405312

  29. Knechel NA (2009) Tuberculosis: pathophysiology, clinical features, and diagnosis. Crit Care Nurse 29(2):34–43

  30. Kolyva AS, Karakousis PC (2012) Old and new TB drugs: mechanisms of action and resistance. In: Understanding tuberculosis-new approaches to fighting against drug resistance, InTechOpen, London, pp 209–231

  31. Leung KL, Yip CW, Yeung YL, Wong KL, Chan WY, Chan MY, Kam KM (2010) Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs. J Appl Microbiol 109(6):2087–2094

  32. Liu F, Heiner M, Gilbert D (2018) Fuzzy Petri nets for modelling of uncertain biological systems. Brief Bioinform 00:1–13

  33. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S (2006) Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. JAIDS 43(1):42–46

  34. Murata T (1989) Petri nets: properties, analysis and applications. Proc IEEE 77(4):541–580

  35. Olszak J, Radom M, Formanowicz P (2018) Some aspects of modeling and analysis of complex biological systems using time Petri nets. Bull Pol Acad Sci Techn Sci 66(1):67–78

  36. Palomino J, Martin A (2014) Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics 3(3):317–340

  37. Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y (2013) Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother 57(2):893–900

  38. Peterson JL (1977) Petri nets. ACM Comput Surv (CSUR) 9(3):223–252

  39. Rovetto C, Cano E, Ojo K, Tuñon M, Montes H (2018) Coloured Petri net model for remote monitoring of cardiovascular dysfunction. Memorias de Congresos UTP 405–411

  40. Russo G, Pennisi M, Boscarino R, Pappalardo F (2018) Continuous Petri Nets and microRNA analysis in melanoma. IEEE/ACM Trans Comput Biol Bioinform (TCBB) 15(5):1492–1499

  41. Shi W, Chen J, Feng J, Cui P, Zhang S, Weng X, Zhang Y (2014) Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerg Microbes Infect 3(1):1–8

  42. Singh GP (2013) Some advances in the theory of Petri Nets. Ph.D. thesis, Delhi College of Engineering, Faculty of Technology, University of Delhi, Delhi

  43. Singh GP (2016) Applications of Petri nets in electrical, electronics and optimizations. In: International conference on electrical, electronics, and optimization techniques (ICEEOT) IEEE, 2180-2184

  44. Singh GP, Gupta A (2019) A Petri net analysis to study the effects of diabetes on cardiovascular diseases. IEEE Xplore, ISBN: 978-93-80544-36-6.(accepted)

  45. Singh GP, Kansal S (2016) Basic results on crisp Boolean Petri Nets. In: Modern mathematical methods and high performance computing in science and technology, Springer, Singapore, pp 83–88

  46. Singh GP, Singh SK (2019) Petri net recommender system for generating of perfect binary tree. Int J Knowl Syst Sci (IJKSS) 10(2):1–12

  47. Singh GP, Kansal S, Acharya M (2013a) Construction of a crisp Boolean Petri net from a 1-safe Petri net. Int J Comput Appl 73(17):1–4

  48. Singh GP, Kansal S, Acharya M (2013b) Embedding an Arbitrary 1-safe Petri net into a Boolean Petri Net. Int J Comput Appl 70(6):7–9

  49. Stanley SA, Raghavan S, Hwang WW, Cox JS (2003) Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc Nat Acad Sci 100(22):13001–13006

  50. Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, Jacobs WR (1997) The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 3(5):567

  51. Timmins GS, Deretic V (2006) Mechanisms of action of isoniazid. Mol Microbiol 62(5):1220–1227

  52. van der Heijden YF, Karim F, Mufamadi G, Zako L, Chinappa T, Shepherd BE, Pym AS (2017) Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. Int J Tuberc Lung Dis 21(6):670–676

  53. Vashishtha VM (2009) WHO Global Tuberculosis Control Report 2009: tuberculosis elimination is a distant dream. Indian Pediatr 46(5):401–402

  54. Wehrli W (1983) Rifampin: mechanisms of action and resistance. Rev Infect Dis 5(Supplement–3):S407–S411

  55. Weyer K, Mirzayev F, Migliori GB, Van Gemert W, D’Ambrosio L, Zignol M, Gilpin C (2013) Rapid molecular TB diagnosis: evidence, policy making and global implementation of XpertMTB/RIF. Eur Respir J 42(1):252–271

  56. World Health Organization & Stop TB Initiative (World Health Organization) (2010) Treatment of tuberculosis: guidelines. World Health Organization, Geneva

  57. Young F, Critchley JA, Johnstone LK, Unwin NC (2009) A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and diabetes mellitus, HIV and metabolic syndrome, and the impact of globalization. Glob Health 5(9):1–9

Download references


The authors express their deep gratitude to anonymous reviewers, editors for their valuable suggestions and comments.


This work is supported by the funding agency Science and Engineering Research Board, Govt. of India, Project ID. (File No.: ECR/2017/003480/PMS).

Author information

Correspondence to Gajendra Pratap Singh.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



See Figs. 10, 11 and 12.

Fig. 10

Classification of net in Fig. 3

Fig. 11

State space analysis of net in Fig. 3

Fig. 12

Ratio metric of net in Fig. 3

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Singh, G.P., Jha, M., Singh, M. et al. Modeling the mechanism pathways of first line drug in Tuberculosis using Petri nets. Int J Syst Assur Eng Manag (2020).

Download citation


  • Tuberculosis disease
  • Drug mechanism
  • First line drug
  • Petri net
  • Reachability graph
  • Marking vector
  • PIPEv4.3.0
  • WoPeD